Peptide · developed by MBX Biosciences
MBX 1416 is an agent given by subcutaneous injection and studied in postbariatric hypoglycemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07029412 | Phase 2 | Postbariatric Hypoglycemia | Completed | MBX |
| NCT06036784 | Phase 1 | Postbariatric Hypoglycemia | Completed | MBX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Postbariatric Hypoglycemia
Updated Oct 18, 2026. Something wrong or missing? Report it on the MBX page.
See MBX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MBX catalysts and pipeline →